Antagonists of HMG1 for treating inflammatory conditions
View Patent ↗There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
1. An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade and is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a single chain antibody, a human antibody and a humanized antibody.
2. An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a monoclonal antibody that inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
3. An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a chimeric antibody that inhibits HMG 1-mediated activation of the inflammatory cytokine cascade.
4. An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a single chain antibody that inhibits HMG 1-mediated activation of the inflammatory cytokine cascade.
5. An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a human antibody that inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
6. An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a humanized antibody that inhibits HMG 1-mediated activation of the inflammatory cytokine cascade.
7. The antibody of claim 1 , wherein said antibody binds to a peptide consisting of the amino acid sequence GKGDPKKPRGKMSSC (SEQ ID NO:4).
8. A pharmaceutical composition comprising the antibody of claim 1 .
9. The antibody of claim 2 , wherein said antibody is an antibody fragment.
10. The antibody fragment of claim 9 , wherein said antibody fragment is an antibody fragment of a chimeric antibody.
11. The antibody fragment of claim 9 , wherein said antibody fragment is an antibody fragment of a single chain antibody.
12. The antibody fragment of claim 9 , wherein said antibody fragment is an antibody fragment of a human antibody.
13. The antibody fragment of claim 9 , wherein said antibody fragment is an antibody fragment of a humanized antibody.
14. The antibody fragment of claim 9 , wherein said antibody fragment is an Fab fragment.
15. The antibody fragment of claim 9 , wherein said antibody fragment binds to a peptide consisting of the amino acid sequence GKGDPKKPRGKMSSC (SEQ ID NO:4).
16. A pharmaceutical composition comprising the antibody fragment of claim 9 .
17. A pharmaceutical composition comprising the antibody of claim 2 .
18. A pharmaceutical composition comprising the antibody of claim 3 .
19. A pharmaceutical composition comprising the antibody of claim 4 .
20. A pharmaceutical composition comprising the antibody of claim 5 .
21. A pharmaceutical composition comprising the antibody of claim 6 .
22. A pharmaceutical composition comprising the antibody of claim 7 .